AI For Pharma Growth
AI For Pharma Growth is a podcast hosted by Dr. Andree Bates, an AI entrepreneur, aimed at helping pharma, biotech and healthcare companies understand how AI-based technologies can save time and grow their brands and business results. The show combines her deep sector experience with straightforward explanations of AI for biopharma executives, from biotech start-ups to large pharmaceutical firms. Episodes cover practical, proven approaches to building results with AI as well as interesting new tools and applications. Guests include experts who have developed powerful AI-powered tools behind time-saving and revenue-generating business outcomes.
Episodes
E239: How to Speed Up Drug Development Without Compromising Compliance
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Clara Bernardes, co-founder and CSO of Biorce, about how AI can accelerate clinical development without sacrificing compliance or scientific rigour.Biorce was born from a deeply personal experience. After Clara's father-in-law received a terminal melanoma diagnosis, access to a clinical trial through compassionate use extended hi
E238: The diagnostic room: The Fifteen Failures Only Human Judgement Catches
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores one of the biggest blind spots in pharma AI: the failures that can survive a normal review process even when the output sounds polished, plausible and well grounded.Dr Andree explains why better models and better retrieval do not remove the need for human judgement. In fact, as AI systems improve, people often scrutinise them l
E237: Beyond the Pill: How AI is Unlocking the Preventative Medicine Opportunity Pharma Can't Afford to Miss
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with cancer biologist and health educator Rebecca Maff about how AI could help shift healthcare from treating disease to preventing it.Rebecca’s interest in prevention began after seeing women in her own family diagnosed with late-stage cancers and serious autoimmune conditions. Her subsequent work has included machine learning models
E236: Why 90% of Trials Still Fail — and What AI Can (and Can't) Fix
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Raviv Pryluk, co-founder and CEO of PhaseV, about why so many clinical trials still fail and where AI can genuinely improve the odds.Raviv argues that failure is often not because the drug itself is wrong. Trials can fail because of the wrong patient population, indication, dose, design, sites, monitoring or interpretation of the
E235: AI created a trust crisis and nobody is talking about it
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dan Pratl, founder and CEO of Quadron Inc, about a trust problem emerging as AI moves deeper into pharma: how do organisations preserve confidence when more work is generated, shaped and accelerated by machines?Dan argues that verified output alone is not enough. Pharma already has human review, MLR, regulatory sign-off and quali
E234: The contrarian case for physics over data: can deterministic, training-free models beat ML in lead optimization?
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Dr. Jacek Marczyk, co-founder and CEO of BioDynLab, about a contrarian view of computational drug discovery: that the next leap may come not from more data and bigger models, but from physics.Dr. Marczyk brings a background in aerospace engineering, automotive, Silicon Graphics and complexity science. His work led to quantitative
E233: The Diagnostic Room: The AI Capability Problem Pharma Hasn't Named
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores the AI capability problem pharma has not properly named: training that works in the room, but fails to hold inside the organisation.Dr Andree explains why one-off workshops, generic AI fluency programmes and broad learning platforms are not enough. They may teach people what AI is, what it can do and where it can fail, but they
E232: The Early Readout: Upgrading the Interim Analysis to Catch Futility and Success Years Sooner
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Tom Coates, CEO of Presentient, about why interim analysis in clinical trials is ready for a major upgrade.Interim analyses allow sponsors to look at trial data mid-flight and assess whether a study is likely to succeed or fail, using pre-specified rules. But Tom explains that many phase two and three commercial trials still do n
E231: The Diagnostic Room: You didn't have an AI problem. You had a capability problem.
In this solo episode of AI For Pharma Growth, Dr Andree Bates explores why many pharma teams do not have an AI problem at all. They have a capability problem.Dr Andree starts with a simple question: when was your team last properly trained on AI for their specific role? Not when they were given access to tools, licences or a generic use policy, but when they were trained to use AI effectively, saf
E230: The Last Untouched Dataset
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nijat Ahmadov, CEO of Nucs AI, about molecular imaging as one of pharma’s most underused data assets.Nijat explains why PET, CT and other molecular imaging data remain largely “untouched”: clinically valuable and created at scale, but still too often trapped in qualitative reads rather than structured, standardised data that can
E229: From Reactive to Proactive: What a QP's Job Should Actually Look Like in 2026
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Jitesh Halai, founder and CEO of OneSC, about what the Qualified Person role should look like in a more proactive, digitally connected pharmaceutical supply chain.Jitesh explains how many QPs are still forced into reactive work: chasing documents, checking versions, searching inboxes, reconciling batch data across disconnected sy
E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer
In this solo episode of AI For Pharma Growth, Dr Andree Bates explains why “we’re doing AI” is not a credible board answer, and why activity, pilots and steering committees are not the same as strategy.Dr Andree breaks down two common answers leadership teams give when asked about AI strategy. The episode explores why crowdsourced use cases often become “use case copying” rather than genuine inter
E227: From Bench to Boardroom: How One Geneticist is Quietly Reshaping the Future of Healthcare
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation.Bret shares how the release of the Human Genome Project first pulled him into genetics, and how clinical work with patients m
E226: The AI Deal Scout: How Machine Intelligence Is Reshaping Biopharma Business Development
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Smbat Rafayelyan, founder and CEO of Bioneex, about how AI is reshaping biopharma business development, deal scouting and asset evaluation.Business development has traditionally relied heavily on relationships, conferences, databases, analyst reports and manual search. But as therapeutic pipelines, publications, patent filings an
E225: The 80% Nobody Talks About: Building AI Governance That Survives a Pharma Audit
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Nuno Valério, Head of Innovation, R&D Quality at Merck Healthcare, about the part of AI governance most organisations rarely talk about: the operational 80% that decides whether AI survives a pharma audit.Nuno explains why governance cannot stop at policies, committees, risk frameworks and model registers. Those visible eleme
E224: The Diagnostic Room: The Financial Case Your CFO Actually Needs to See Before Approving Your AI Strategy
In this solo episode of AI For Pharma Growth, Dr Andree Bates tackles one of the biggest reasons pharma AI strategies stall: they are not presented in the financial language a CFO can approve.Dr Andree argues that the issue is rarely whether AI has value. The issue is that most organisations cannot quantify that value in a way that connects to business outcomes, baselines, investment priorities, t
E223: From Population Models to Personal Intelligence: Rethinking Biological Data
For most of modern medicine, biological data has been built around population averages: what people like you might experience, rather than what you personally will. In this episode, Dr Andree Bates speaks with Ken Clark, co-founder and CEO of Enigma Genetics, about moving from population models to personal intelligence, and what it could mean for patients, pharma and the future of biological data.
E222: Why Most Pharma AI Will Fail Without This One Thing
Most pharma companies are racing to apply AI across drug discovery, development and commercialisation, but many of those efforts will fail for one simple reason: the data underneath is not good enough. In this episode, Dr Andree Bates speaks with Lisa Downey, CEO of DrugBank, about why trusted, structured biomedical intelligence is the foundation pharma AI cannot succeed without.Lisa explains how
E221: The Diagnostic Room: The AI Governance Timeline Moved. Your Governance Exposure Didn't
On 7 May 2026, the EU reached a provisional agreement to push back the hardest deadlines in the EU AI Act. Many leadership teams heard one message: “we’ve got more time”. In this solo episode, Dr Andree Bates explains why that exhale is dangerous. The timeline moved, but the governance exposure did not.Dr Andree breaks down what the delay does and does not change. The dates may shift, but the arch
E220: The Intelligence Gap: Why Pharma's Biggest Deals Are Being Lost Before They Even Know They're Competing
In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the “intelligence gap” in business development, licensing, and corporate strategy, and why many companies are losing opportunities before they even know they’re competing.Andrey shares how his background b
E219: Bridging the Data-Use Divide: How QuadraticMed’s Dr. Danielle Bower Bridges Medicine and Data Science to Unlock Real-World Evidence
Real world evidence (RWE) could transform drug development and clinical care, but most organisations still struggle to turn messy clinical data into decisions they can trust. In this episode, Dr Andree Bates speaks with Dr Danielle Bower, CEO of QuadraticMed, about bridging the “data use divide” between clinical expertise and data science, so real world data becomes usable evidence rather than noi
E218: How astrophysics methods used to study dark matter are now being applied to model cancer biology
Some of the most powerful breakthroughs happen when methods built for one discipline get turned on another. In this episode, Dr Andree Bates interviews Dr Irina Babina, CEO of Concr, on how computational techniques originally developed in astrophysics are being applied to oncology, helping predict how individual cancer patients will respond to treatment.Irina shares her journey from genetics and t
E217: The Diagnostic Room: Pilot purgatory: why pharma AI stalls after the first wins
Pharma doesn’t have an AI experimentation problem. It has an AI execution, scaling, and ROI justification problem. In this solo episode, Dr Andree Bates names one of the most expensive failure patterns in the industry: pilot purgatory.A key theme is misdiagnosis. When AI stalls, organisations often blame platforms, data science capability, training, vendor selection, or “resistance to change”. Dr
E216: When AI meets Cell Engineering
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei, Founder and CEO of Portal Biotechnologies, about what happens when AI meets cell engineering, and why point-of-care delivery could make personalised cell programming more practical, scalable, and safer.A
E215: Location, Location, Innovation: AI Site Twins and the New Era of Site Selection
Clinical trial site selection is one of the biggest hidden bottlenecks in drug development, and it’s still often driven by legacy relationships, spreadsheets, and habit. In this episode, Dr Andree Bates interviews Simon Arkell, founder of Ryght, Inc, about “AI Site Twins” and why the next era of site selection shifts from institutional memory to predictive, real-time analytics.Simon explains why t
E214: Beyond Copilot
For many life sciences teams, the first wave of AI has looked like copilots: smart search, quick answers, and help on demand. Useful, but passive. In this episode, Dr Andree Bates is joined by Parth Khanna, CEO and co-founder of ACTO, to explore what comes next: moving beyond copilots into role-based AI agents that proactively close knowledge gaps, improve field readiness, and operate safely insid
E213: The Diagnostic Room: We have AI initiatives, but do we have a strategy? The quickest self-test
Many pharma and life science organisations have been investing in AI for years: pilots across commercial, medical, regulatory, and R&D, innovation labs, steering committees, vendor spend, and genuine effort from smart teams. And yet the same story keeps showing up in boardrooms: ROI is unclear, adoption is patchy, and leaders struggle to explain how all the AI activity connects to strategic go
E212: The Ethics of AI
AI ethics has moved from theory to urgent necessity, especially as AI systems become embedded in healthcare, business decisions, and society at large. In this episode, Dr Andree Bates is joined by Dr Nadia Morozova, founder of Enriched Insights, to unpack what ethical AI really means in practice, and how organisations can innovate quickly without creating risk, bias, or governance failures.Nadia s
E211: Precision Monitoring: How Digital Biomarkers Are Changing Medicine
Digital biomarkers are turning everyday movement into clinically useful data, giving doctors a clearer picture of what’s happening between appointments, and giving pharma new ways to measure drug impact earlier and more precisely. In this episode, Dr Andree Bates interviews Dr Quique Llaudet, CEO and co-founder of Ephion Health, about precision monitoring and how AI-driven mobility analysis is cha
E210: Beyond Alzheimer’s: Scaling Digital Twins Across Disease Areas
Digital twins have become one of the most promising tools in Alzheimer’s research, but the bigger story is what happens when they scale across disease areas. In this episode, Dr Andree Bates interviews Aaron Smith, Founder and Head of Machine Learning at Unlearn AI, about how “digital twin generators” can transform trial design by modelling realistic patient progression and improving statistical p
E209: Beyond Failure Prevention: How AI is Redesigning the Drug Discovery Pipeline
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.Vitalay shares hi
E208 : The future of enterprise AI: agents, automation, and trust
Enterprise AI is shifting from experiments to infrastructure, and that changes everything. In this episode, Dr Andree Bates interviews Jocelyn Houle, Senior Director of Product Management at Securiti.ai, to explore the future of enterprise AI, agents, automation, and the single biggest blocker to scale: trust.Jocelyn shares what she is seeing across highly regulated industries as organisations mov
E207: The economics of clinical trials and the relationship to AI
Clinical trials are a massive industry with brutal economics, long timelines, and failure rates that would be unacceptable in almost any other sector. In this episode, Dr Andree Bates is joined by Dr Joseph Geraci of NetraMark to break down why trials fail so often, how patient heterogeneity drives cost and uncertainty, and where AI can realistically shift the economics.Joseph shares his unusual p
EP206: Why Your Pharma AI Strategy Is Probably Broken — And What a Real Blueprint Looks Like
AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.Dr Andree explains the
E205: Healthcare Accessibility & Innovation
Healthcare accessibility is still being held hostage by phone queues, missed calls, and clunky portals. In this episode, Dr Andree Bates sits down with Josh Taylor of TxtSquad to explore why simple, secure texting can remove friction for patients and providers, and how AI can support the conversation without making care feel robotic.Josh explains why SMS works where apps often fail: it is familiar
E204: Human-Centered AI: Designing Intelligence That Aligns With Us
As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews Dr Morteza Zihayat of Heisenberg Network to explore Human-Centred AI: designing intelligent systems that prioritise welfare, autonomy, dignity and trust over pure technical capability.Morteza explains
E203: Building Programmable Biologics from Scratch: How DenovAI's AI is Revolutionizing Drug Discovery
Designing proteins that have never existed in nature is no longer sci-fi — it’s becoming a real drug discovery strategy. In this episode, Kashif Sadiq, Founder & CEO of DenovAI Biotech, explains how AI is powering a shift from searching for biologic binders to intentionally designing new proteins from scratch.Kashif shares his journey from studying physics at University of Cambridge into compu
E202: Recent Advances in LLMs and How They Will Impact Science and Pharma Research
Large Language Models (LLMs) are moving far beyond text generation—and into the heart of scientific discovery and pharmaceutical research. In this episode, Javier Tordable, founder and CEO of Pauling.ai and former Google technologist, explains how agentic AI systems are transforming early-stage drug discovery.Javier shares how modern LLMs differ from earlier generations, highlighting their ability
E201: The Small Molecule Revolution: ProPhet's Tom Shani on AI-Powered Drug Discovery
Artificial intelligence is rapidly reshaping the pharmaceutical industry—and nowhere is that more evident than in small-molecule drug discovery. In this episode, we sit down with Tom Shani, CEO and co-founder of ProPhet, an AI-driven biotech company focused on discovering drugs for hard-to-target proteins.Tom explains how machine learning models, transformers, and AI-driven molecular representatio
E200: Podcast with Cures & Capital Part 3
In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry.Dr. Andre Bates shares a pragmatic view on AI in the biopharma industry, cutting through the hype to explore where AI is already delivering v
E199: Podcast with Cures & Capital Part 2
In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry.Dr. Bates shares actionable insights into the real-world potential of AI to reduce time-to-market, cut development costs, and create competit
E198: Podcast with Cures & Capital Part 1
In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simon for a deep dive into how AI is transforming the biopharma industry. With over two decades of experience applying AI across R&D, clinical development, regulatory, medical affairs, and commercial teams, Dr. Bates explains how the field has evolved from early digitisation to the current
E197: Inside the AI Factory: How AI Systems Builds Workflows That Actually Work
In this episode, we take you inside the AI factory — the place where companies are transforming real business operations using AI workflows, not just experimenting with flashy demos or proofs of concept.AI strategist Dustin Jensen breaks down what differentiates AI systems that scale from those that become expensive experiments. He explains why companies waste money when they “throw AI at a workfl
E196: Simplify to Scale: Using AI and Design Thinking to Cut Complexity and Grow Smarter
In today’s episode, we explore the Simplify to Scale approach — how companies can use AI, intelligent automation, and design thinking to remove operational friction, improve workflows, and unlock sustainable growth. Our guest, Anthony Franco, is a serial entrepreneur, AI strategist, and co-author of AI First Principles and The Wiser Method. He has launched and successfully exited six companies, an
E195: How Organs-on-Chips Are Revolutionizing Drug Development
What if drug testing didn’t need animals — or risky early-stage human trials?In today’s episode, we explore organ-on-a-chip technology, a breakthrough innovation that is transforming how drugs are developed, tested, and brought to market. These micro-sized devices — containing real living human cells — can accurately replicate the function of organs like the liver, lungs, brain, kidney, and intest
E194: The Digital Twin Revolution: Reimagining Clinical Trials
In this episode, we explore one of the most disruptive advancements currently reshaping the pharmaceutical and biotech industry: AI-powered digital twins for clinical trials.Our guest, Aaron Smith, PhD — Founder and Head of Machine Learning at Unlearn.AI — breaks down how digital twins and generative AI are transforming drug development by enabling faster, smaller, and more efficient clinical tria
E193: The AI Doctor in Your Throat: Real-Time Cancer Detection
What if artificial intelligence could detect throat cancer instantly — in real time — during a routine exam?In this groundbreaking episode, we speak with Marius Wellenstein, Founder and CEO of WSK Medical, the company behind the world’s first AI-powered endoscopic solution for real-time detection and classification of throat and head & neck cancers.Marius shares how his team developed a plug-a
E192: Building Biotech: What It Takes to Lead a Public Life Sciences Company
In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers.From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he’s leveraging artificial intelligence, data analytics, and computational biology to reshape cell t
E191: Quantum Computation In Medicine: The Challenges, What Comes After Large Language Models For Medicine
In this episode, we explore the future of medicine beyond artificial intelligence with Joseph Geraci — mathematician, medical scientist, and quantum machine learning pioneer.While today’s AI breakthroughs and large language models (LLMs) have transformed diagnostics, data analysis, and drug discovery, quantum computing could completely redefine what’s possible in healthcare.Dr. Geraci breaks down
E190: AI-Powered Women's Health: Closing the Gender Data Gap in Medical Research
For decades, medical research has been built around male data — leaving women dangerously underrepresented in clinical trials, drug development, and symptom understanding. The result? Misdiagnoses, ineffective treatments, and life-threatening blind spots in women’s healthcare.In this episode, Sonja Rincon, CEO and founder of MenoTracker, reveals how artificial intelligence is finally beginning to
E189: The Mirror Never Lies: How AI Reveals Your Health From Your Face
What if your smartphone camera could detect your blood pressure, heart rate, stress levels, and early signs of disease — all in under a minute?In this groundbreaking episode, Remi Koscielny, CEO and Co-founder of Shen.AI, reveals how artificial intelligence is transforming everyday devices into powerful, non-invasive health monitoring tools. With over 5 billion smartphones in use worldwide — but h
E188: How AI is Used in Digital Marketing
In this episode, we dive deep into how artificial intelligence (AI) is revolutionising digital marketing, from SEO optimisation to automated content creation, predictive analytics, and personalised campaigns.Our guest, Brandon Leibowitz, founder of SEO Optimisers, shares his expert insights on the future of AI-powered marketing, the best AI tools for SEO, and how to write effective ChatGPT prompts
E187: Digital Guardians: Where AI Meets Cybersecurity
In this episode, we dive into the escalating war between AI and cybercrime — where artificial intelligence is both the ultimate defense and the greatest vulnerability.Our guest, Grant McCracken, founder of Dark Horse Security, reveals how AI-driven cybersecurity, machine learning detection systems, and automated threat analysis are transforming how we fight cyber threats in real time.From dee
E186: How Manufacturing Innovation is Making Personalized Medicine Scalable and Affordable
Carlo Buckley, Founder and CEO of ID Health, joins the show to reveal how his company is transforming the future of personalised medicine through AI-driven, automated pharmaceutical manufacturing.For decades, personalised medicine has been limited by outdated manufacturing methods designed for mass production, not individual treatment. ID Health is changing that — pioneering a new way to produce p
E185: Use of xAI in Small Cohort Clinical Trials to Identify Biomarkers of Best Responders
In this episode, we explore how Explainable AI (XAI) is revolutionizing drug development, rare disease research, and precision medicine.Our guest, Frédéric Parmentier, Vice President of Data Science at Ariana Pharma, shares how their Explainable Artificial Intelligence (XAI) platform, KEM (Knowledge Extraction and Management), helps uncover critical biomarker signatures in small cohort clinical tr
E184: How Contactless AI Sleep Monitoring is Transforming Patient Data Collection and Drug Development in Clinical Trials
How can AI-powered sleep monitoring transform clinical trials, drug development, and healthcare at home?In this episode, Jonas Krauss, Vice President of Business at Sleepiz AG, joins us to explore how contactless AI monitoring is redefining the way researchers and clinicians collect and analyze sleep data, vital signs, and patient health trends.Using radar-based sensors and artificial intelligence
E183: Accelerating Biomanufacturing with AI: Reducing Development Timelines from Years to Hours
Can artificial intelligence really cut biomanufacturing timelines from years to hours? The answer is yes — and it’s already happening.In this episode, we sit down with Justin Byers, founder and CEO of Axio BioPharma, to explore how AI-driven biomanufacturing is transforming the development of monoclonal antibodies, biologics, and vaccines. By leveraging machine learning, digital twins, and predict
E182: Why Clinical Drug Development Keeps Failing
Over 90% of drugs fail during clinical development, costing billions and leaving patients without life-saving treatments. Why does the pharmaceutical industry face such a high drug development failure rate, and how can artificial intelligence change the story?In this episode, Vitalay Fomin, CEO and co-founder of Numenos AI, reveals how his team is rethinking clinical trials, biomarker discovery, a
E181: The future of IP Law: What's Next for Trademarks, Copyrights, and Patents as AI Continues to Disrupt Industries?
As artificial intelligence transforms the way we create, invent, and innovate, it’s also forcing the legal world to face unprecedented challenges. In this episode, Dr. Don Simmonds, IP law expert and founder of IPITEC, dives deep into the future of intellectual property law in the age of AI.From AI-generated art and machine-written books to patent disputes over AI-created inventions, this conversa
E180: Pharma and AI: Drug Discovery with Confidential AI Practices with Edge AI Implementations
In this cutting-edge episode, we explore how Edge AI is transforming drug discovery and revolutionising laboratory workflows, real-time molecular analysis, and protein folding predictions—all at the source of data collection. Joining us is Nuri Cankaya, Vice President of Commercial Marketing at Intel Corporation, and a renowned thought leader in AI and healthcare innovation.You'll discover how AI
E179: Beyond Anonymization: Why Traditional Privacy Isn't Enough for AI Healthcare
In this eye-opening episode, we sit down with Julia Komissarchik, CEO and Co-Founder of Glendor Inc., to explore the rapidly evolving intersection of AI in healthcare, medical data privacy, and patient data protection. With AI transforming clinical decision-making, diagnostics, and health research, traditional privacy approaches like de-identification are no longer sufficient.Julia, a seasoned exp
E178: Navigating Reliability in Modern Molecular Research with AI
Can AI truly revolutionize molecular biology if it’s built on unreliable data? In this game-changing episode, we speak with Dr. Jonathon O'Brien, founder and CEO of Golgi, about one of the most critical—and often overlooked—issues in biomedical AI: data reliability.With a background in biostatistics, proteomics, and machine learning, Dr. O’Brien shares how Golgi’s AI-powered computational platform
E177 | Maximising Healthcare Value with Real World Data
In this episode, we delve into the transformative power of real-world data (RWD) in modern healthcare. Our guest, Ted Sweetser, Vice President of Strategic Advertising and Partnerships at PurpleLab, shares expert insights on how real-world data is driving innovation in patient outcomes, market access, and public health strategy.From electronic health records (EHRs) and insurance claims data to wea
E176 | FDA Guidance on AI in Drug Development & Orphan Drug Development
In this episode, former FDA leader and current SVP of Regulatory and Quality at Ariana Data Intelligence, Dr. Frederico Goodsaid, shares cutting-edge insights on how artificial intelligence (AI) is reshaping the landscape of drug discovery and development — particularly in the treatment of rare and orphan diseases.From breaking down the FDA's new guidance on AI to explaining why credibility now ma
E175 | Technology and Human Evolution
Why empathy, ethics, and education must remain central to AI adoptionPredictions for the next 500 years of human-AI co-evolutionThis conversation blends AI philosophy, tech strategy, and personal productivity in a way that will challenge your assumptions and give you actionable ideas to stay relevant in the AI-pIn this eye-opening episode, we’re joined by Mark Andrews, founder and CEO of AI Prophe
E174 | How AI is Transforming Regulatory Submission and Medical Writing in Biopharma
In this powerful episode, we dive deep into how artificial intelligence (AI) and automation are transforming regulatory submissions and medical writing in the biopharmaceutical industry.Our guest, Tim Martin, Vice President of Product at Yseop, shares expert insights on how AI-driven tools are revolutionising workflows, cutting document creation times by over 70%, and helping accelerate drug appro
E173 | How AI is Changing/Revolutionizing Drug Discovery
In this episode, we sit down with Dr. Marschall Runge - CEO of Michigan Medicine and Dean of the University of Michigan Medical School - to explore how artificial intelligence (AI) is transforming the entire landscape of drug discovery, clinical trial design, and precision medicine.With deep insights from decades of leadership across biotechnology, genomics, and translational research, Dr. Runge s
E172 | The problems that modern AI methods have with patient populations in oncology and neuroscience
This powerful episode dives into one of the most urgent issues in modern healthcare; how current AI systems in clinical trials are missing the mark for diverse and underrepresented patient populations, especially in oncology and neurology.Guest Dr. Joseph Geraci, mathematician, quantum machine learning scientist, and inventor of Netramark, breaks down how most AI models today are built on bia
E171 | Leveraging AI to Detect Mental States and Prevent Catastrophic Events in Mental Health
Leveraging AI to detect mental states and prevent catastrophic events in mental healthThis episode dives into a revolutionary advancement in AI-powered mental health technology. Francois Gand, founder and CEO of Nuro, introduces Mentis - a non-invasive neurotechnology platform capable of detecting, tracking, and predicting mental states in real time.From preventing suicide and catastrophic errors
E170 | Leveraging AI for patient finding and knowledge generation for rare diseases
In this expert-led episode, Christopher Rudolf, CEO of Volv Global, unpacks how artificial intelligence is revolutionizing rare disease detection and knowledge generation. With over 30 years in data science and medical informatics, he shares how machine learning is being used to solve two of the biggest challenges in rare disease: finding undiagnosed patients and generating actionable clinical ins
E169 | Scaling Life-Saving AI Through Synthetic Imaging
This episode dives deep into how synthetic medical imaging is revolutionizing the development of AI in healthcare. Rayan Sadri, founder and CEO of Carez AI, explains how his team uses diffusion models and GANs to create fully anonymized, regulator-friendly datasets that dramatically accelerate the development of diagnostic tools - even for rare conditions and underserved populations.Discover how s
E168 | Copyright Implications of Employee AI Use
In this essential episode, we dive deep into the evolving intersection of AI in the workplace and copyright law with expert guest Lauren McLeod Tulloch, Vice President and Managing Director at the Copyright Clearance Center.As businesses increasingly adopt generative AI tools like ChatGPT, Claude, and other LLMs, the legal and compliance landscape is rapidly shifting. Lauren shares actionable insi
E167 | The most advanced AI for legal and compliance
In this eye-opening episode, we explore how cutting-edge AI is revolutionizing the legal and compliance industry, particularly for contract lifecycle management, litigation preparation, and regulatory compliance.Our guest is Jaegar Glucina, Chief of Staff at Luminance—an AI-powered legal software platform trusted by over 700 organizations worldwide, including global law firms and corporate legal d
E166 | AI and AR to help surgeons achieve better patient outcomes
In this episode, discover how AI (artificial intelligence) and AR (augmented reality) are transforming neurosurgery, surgical training, and the entire operating room experience. Vladimir Verbulskii, CEO of Argus AI, shares how their cutting-edge technology is enabling surgeons to see inside the human body with unmatched clarity, boosting precision, reducing risks, and improving patient outcomes.Ex
E165 | AI & Wearable Data in Pharma: How real-time biometric insights can enhance patient monitoring and early intervention
In this cutting-edge episode of the podcast, we explore the powerful intersection of artificial intelligence (AI), wearable technology, and the pharmaceutical industry. Our special guest, Marco Benitez, CEO and co-founder of Rook AI, shares how real-time biometric data from wearables like Apple Watch, Dexcom, and Oura Ring is revolutionizing clinical trials, remote patient monitoring, and digital
E164 | AI for automating clinical trial processes and optimizing clinical trial design - that excels even with rare condition trials
In this must-listen episode of AI for Business Growth, host Dr. Andre Bates is joined by Damond Rasheed, Executive Director at Opyl (makers of Trial Key, an AI SaaS platform for clinical trial design). Together, they unpack how artificial intelligence is transforming rare disease clinical trials, solving real-world bottlenecks in patient recruitment, adaptive trial design, and biostatistical valid
E163 | AI Search & Healthcare: Ranking Where It Matters Most
In this episode of AI for Business Growth, Dr. Andre Bates sits down with Michael Buckbee, co-founder of Knowatoa, to explore the fast-evolving world of AI-powered search, especially in healthcare and SEO strategy. From ChatGPT hallucinations to brand sentiment in AI rankings, this conversation dives deep into the real-world use cases, risks, and transformational opportunities of using large langu
E162 | How AI can simplify CNS participant screening for Alzheimers and Parkinsons
In this must-listen episode, Dr. Andre Bates sits down with James Hamet, founder and CEO of Vistim Labs, as he unveils a groundbreaking EEG technology that could transform how we understand and treat neurodegenerative diseases like Alzheimer's and Parkinson's. In this eye-opening edition of AI for Business Growth, Hamet reveals a cutting-edge brain mapping technique that can reproduce PET sca
E161 | How GenAI can change medical imaging
In this must-listen episode, Dr. Andre Bates sits down with Soner Hacihaliloglu, founder and CEO of PONS Tech, to explore how Generative AI (GenAI) and ultrasound technology are combining to radically improve medical imaging, early detection, and preventive healthcare.🚀 Key Takeaways:How AI-driven image enhancement is solving the challenges of low-quality ultrasound images.Why mobile and decentral
E160 | From Bio-Tech to Tech-Bio: AI Meets Drug Discovery
Welcome to an eye-opening conversation at the intersection of artificial intelligence and biotechnology. In this episode, we explore how AI is redefining protein design, accelerating drug discovery, and personalizing medicine at scale.Joining us is Brian Keane, Chairman of the Board at Diagen AI — a trailblazing Canadian company using AI-powered molecular modeling to revolutionize therapeutic deve
Recommended
The Bread and Banter Podcast
The Church of What's Happening Now: The New Testament
Busted Open
Deadline: White House
Crickets Corner
History of the Earthquake and Fire in San Francisco
Fox news
K-Drama Obsessed Mamas | Beyond “Just One More Episode!”
True Crime Classics
The Healer Revolution
Becoming: HER with Nikki Spoelstra
Booked, Blonde & Busy w/ Olivia Ponton
